Protective effects of sevoflurane in cerebral ischemia reperfusion injury: a narrative review

Tian-Yu Liang^{1, #}, **Song-Yang Peng**^{1, #}, **Mian Ma**^{2, *}, **Hai-Ying Li**^{1, *}, **Zhong Wang**¹, **Gang Chen**¹ 1 Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China

2 Department of Neurosurgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu Province, China

*Correspondence to: Mian Ma, MD, 343739595@qq.com; Hai-Ying Li, PhD, lhy1015@qq.com. #Both authors contributed equally to this work.

orcid: 0000-0001-6327-7005 (Mian Ma); 0000-0002-5555-6802 (Hai-Ying Li)

Abstract

Ischemia/reperfusion (I/R) injury is a phenomenon that the reperfusion of ischemic organs or tissues aggravates their damage, which poses a serious health threat and economic burden to the world. I/R gives rise to a series of physiological and pathological world, including inflammatory response, oxidative stress, brain edema, blood-brain barrier destruction, and neuronal death. Therefore, finding effective treatment measures is extremely important to the recovery of I/R patients and the improvement of long-term quality of life. Sevoflurane is an important volatile anesthetic which has been reported to reduce myocardial I/R damage and infarct size. Sevoflurane also has anti-inflammatory and neuroprotective effects. As reported sevoflurane treatment could reduce nerve function injury, cerebral infarction volume and the level of inflammatory factors. At the same time, there is evidence that sevoflurane can reduce neuron apoptosis and antioxidant stress. The protective effect of sevoflurane in brain injury has been proved to be existed in several aspects, so that a comprehensive understanding of its neuroprotective effect is helpful to exploit new treatment paths for I/R, provide clinicians with new clinical treatment decisions, contribute to the effective treatment of I/R patients and the improvement of quality of life after I/R healing.

Key words: central nervous system; cerebral blood flow; cerebral ischemia-reperfusion injury; inflammatory response; inhalant anesthetic; microglia; neuroprotection; sevoflurane

doi: 10.4103/2045-9912.318860

How to cite this article: Liang TY, Peng SY, Ma M, Li HY, Wang Z, Chen G. Protective effects of sevoflurane in cerebral ischemia reperfusion injury: a narrative review. Med Gas Res 2021;11(4):152-154.

Funding: This work was supported by Suzhou Youth Science and Technology Project, China (No. KJXW 2017029).

INTRODUCTION

Cerebral ischemia/reperfusion (I/R) injury can cause the most common stroke-related death and disability worldwide and has a poor prognosis.^{1,2} Prompt ischemia-reperfusion can prevent severe neurological defects and death. However, it may further exacerbate neuron death and neurological dysfunction.³ Due to blocked cerebral arteries and inadequate blood supply, I/R in the brain leads to complex pathophysiological processes leading to further I/R injury.⁴ In addition, autophagy and inflammation emerge after I/R contribute to further damages to the neuron death and cell death.⁵ In the process of cerebral I/R, there are a large number of inflammatory factors in the ischemic focus.^{6,7} While restoring blood flow to ischemic organs is critical to preventing irreversible tissue damage, reperfusion itself may lead to local and systemic inflammatory responses that may increase tissue damage beyond that caused by ischemia alone.⁸ I/R injury is characterized by oxidation products, complement activation, leukocyte-endothelial cell adhesion, platelets-leukocyte aggregation, increased microtubule permeability, and decreased endotheliumdependent diastolic function. The most severe I/R damage can lead to multiple organ dysfunction or death.9

Sevoflurane is an inhaled anesthetic widely used in surgery.¹⁰ Sevoflurane has the activity of anti-oxidative stress and antiinflammation, and can protect organs from the damage caused by stress.¹¹ It is now recognized that sevoflurane is a safe inhaled anesthetic and has the advantages of inducing rapid and rapid resuscitation as an anesthetic inducer.¹² Existing studies have indicated that sevoflurane preconditioning for neurological protection is a double-edged sword for patients with neurological defects. For one thing, sevoflurane can relieve the inflammatory response,¹³ reducing cell death, the activation of innate immune cells. For another thing, sevoflurane can inhibit the release of related cytokines, increase cognitive dysfunction and amplify brain damage.¹⁴ However, the mechanism of sevoflurane's function after I/R has not been fully studied. This paper presents a comprehensive description of several existing mechanisms, which is conducive to the full understanding of sevoflurane. More importantly, it is helpful for clinicians to grasp the use of sevoflurane and promote the safe and effective use of sevoflurane in clinical practice.

Mechanisms of Sevoflurane

Existing studies have shown that sevoflurane is a vasodilator, and in vitro and in vivo experiments have shown that sevoflurane can effectively protect neurons following cerebral ischemia through several pathways. Although its protective effect has been an issue of concern, the mechanism of sevoflurane remains to be further studied. Signal transduction pathway is the main way for cells to transmit information. At present, several signal transduction pathways for sevoflurane to play a neuroprotective role have been discovered, such as Janus kinase-signal transducer and activator of transcription pathway,15 Toll like receptor 4/nuclear factor-KB pathway,16 TWIK-related K⁺ channel 1 channel,¹⁷ phosphoinositide 3-kinase/Akt signaling pathway,¹⁸ Akt signaling pathway,¹⁹ protein kinase B/nuclear factor-erythroid 2-related factor 2 pathway.²⁰ Through these signaling pathways, sevoflurane reduces inflammation, activates glial cells, inhibits neuronal apoptosis, and protects damaged brain tissue.

Sevoflurane attenuates the inflammatory response

It is widely known that sevoflurane has the benefits of antiinflammatory and neuroprotection. In 2004, Nader et al.²¹ pointed out that volatile anesthetics, such as sevoflurane, could attenuate the inflammatory response, in their report, the inhalation of sevoflurane could reduce the expression of inflammatory factors of tumor necrosis factor- α and interleukin-1 β in plasma. In vivo studies have also shown that sevoflurane post-treatment can reduce the inflammatory response in the cerebral infarction area and reduce the concentration of serum pro-inflammatory cytokines in rats after cerebral I/R injury.¹⁶ It has been reported that sevoflurane treatment can enhance the barrier function of the brain, protect the vascular endothelial integrity, and maintain the cell junction protein arrangement, which effectively increases cerebral blood flow, and also enhances the anti-inflammatory ability of the body.22 Numerous subsequent studies have shown that sevoflurane has an anti-inflammatory effect to protect damaged brain tissue after I/R by reducing the production of inflammatory factors through various pathways. This is the key step in the recovery of patients with cerebral I/R injury.^{16,18}

Sevoflurane helps macrophages/microglia perform immune function

Microglia and macrophages are the most effective central nervous system damage repair and regeneration regulators and undertake an important character in innate immunity and acquired immunity.23 After I/R, the activated microglia not only release neurotrophic factors, but also secrete a variety of pro-inflammatory cytokines, nitric oxide and other factors that can aggravate the injury.²⁴ In case of I/R, infiltration and migration of microglia to the spinal cord is associated with damage to the vasculature, caused by substances released by activated microglia, matrix metalloproteinases. The researchers found that sevoflurane pretreatment prevented an increase in the number of harmful microglia in the spinal cord of rats with I/R damage.25 Current studies also suggest that sevoflurane preconditioning may affect motor function by inhibiting microglial cell infiltration and migration of injured neurons, and sevoflurane preconditioning inhibits the production of pro-inflammatory chemokines and cytokines and neuronal cell apoptosis after spinal cord I/R.25 However, there is increasing evidence that microglia/macrophages have dual functions, one is to amplify ischemic damage by releasing proinflammatory neurotoxins, and the other is to support brain recovery after stroke by removing cell debris and secreting nutrient factors.^{26,27} It was found that after sevoflurane administration, reactive microglia/macrophages began to accumulate in and around the lesion site on the 3rd day after stroke, showing a highly branched form and rapid response.25,28 The phagocytosing microglia/macrophages with amoeboid morphology have been confirmed to promote neural survival by clearing

brain damage.²⁹ After sevoflurane pretreatment, its derivative microglia/macrophages rapidly transformed into amoebia-like morphology on the third day after I/R injury and accumulated in the infarcted cortex and striatum, indicating that sevoflurane improves the phagocytic efficiency by increasing the phagocytic capacity of each cell. Compared with the control group, the number of phagocytes in the infarction area of sevoflurane pretreatment group increased significantly on the 5th day after injury, indicating that sevoflurane pretreatment could collect more phagocytes and enhance their phagocytic ability.³⁰

potential toxic debris and reducing subsequent secondary

Other mechanisms that sevoflurane protects central nervous system

Sevoflurane has attracted more and more attention in clinical application as an inhaled anesthetic in recent years.³¹ Existing studies have revealed that sevoflurane can reduce the release of excitatory neurotransmitters such as catechol and glutamine caused by cerebral ischemia injury and relieved the re-stimulation to neurons.³² After cerebral I/R, the production of reactive oxygen species increases dramatically, which is exceeding the endogenous antioxidant system and leading to oxidative stress. The brain is particularly vulnerable to oxidative stress because it consumes a lot of oxygen, rich in polyunsaturated fatty acids and low levels of endogenous antioxidants.33 Sevoflurane can reduce the release of free radicals, showing antioxidant properties.34 Sevoflurane can also inhibit the voltage-gated calcium channel and protein kinase C in the presynaptic membrane of neurons, up-regulate the hippocampal anti-apoptotic proteins Bcl-2 and murine double minute-2, and inhibit the expression of ischemia-mediated apoptotic activating protein Bax, thus protecting the central nervous system (Table 1).³⁵

FUTURE AND PROSPECT

Although the molecular mechanism of sevoflurane to protect injured brain tissue has not been fully elucidated, its application value has been paid more and more attention, including improving cerebral blood flow, inhibiting inflammatory response, reducing infarct area, etc. It is expected that sevoflurane will be widely used in the treatment and recovery of clinical patients.

Author contributions Manuscript drafting: TYL and SYP; manuscript writing: HYL and MM; manuscript revision: ZW and GC. All the authors read and approved the final version of the manuscript for publication. Conflicts of interest The authors have no conflicts of interests to declare. **Financial support** This work was supported by Suzhou Youth Science and Technology Project, China (No. KJXW 2017029). Copyright license agreement The Copyright License Agreement has been signed by all authors before publication. Plagiarism check Checked twice by iThenticate. Peer review Externally peer reviewed. Open access statement This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and

Disease	Intervention	Model animal/cell	Result
MCAO	On 4 consecutive days before MCAO, the rats inhaled a mixture of sevoflurane, oxygen and air.	Rat	Sevoflurane preconditioning can alleviate cerebral I/R injury and promote the repair of damaged brain tissue.
OGDR	Sevoflurane preconditioning: 2.5% sevoflurane with 5% CO ₂ /95% air for 30 min, repeating for 3 times, with 15 min washout after each exposure.	Neuron	Sevoflurane preconditioning alleviated cell injury in OGDR model, which is manifested in increased cell vitality, decreased lactate dehydrogenase release and decreased apoptosis rate after sevoflurane treatment.
MCAO	The sevoflurane post-conditioning: 2% sevoflurane was infused for 15 min before reperfusion.	Rat	Sevoflurane post-conditioning can decrease the level of inflammatory response the concentration of proinflammatory cytokines.
MCAO	Sevoflurane treatment group was given 2% sevoflurane for 15 min before reperfusion	Rat	Sevoflurane treatment could decrease the percentage of cerebral infarction volume, contents of inflammation factors in brain tissue and the apoptotic index of brain tissue after I/R injury.
MCAO	Rats were administered with 1.2% sevoflurane + 98.8% O ₂ in a sealed chamber for 60 min on 4 consecutive days.	Rat	Sevoflurane preconditioning had positive effects on macrophages/microglia.

. ..

Note: I/R: Ischemia/reperfusion; MCAO: middle cerebral artery occlusion; OGDR: oxygen-glucose deprivation/ reperfusion.

build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

REFERENCES

- Yang Z, Weian C, Susu H, Hanmin W. Protective effects of mangiferin on cerebral ischemia-reperfusion injury and its mechanisms. Eur J Pharmacol. 2016;771:145-151
- Stegner D, Klaus V, Nieswandt B. Platelets as modulators of cerebral isch-2. emia/reperfusion injury. Front Immunol. 2019;10:2505.
- 3 Wang J, Xu Z, Chen X, et al. MicroRNA-182-5p attenuates cerebral ischemia-reperfusion injury by targeting Toll-like receptor 4. Biochem Biophys
- Res Commun. 2018;505:677-684. Huang J. Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol. 2006;66:232-245. Wu H, Tang C, Tai LW, et al. Flurbiprofen axetil attenuates cerebral isch-4
- 5. emia/reperfusion injury by reducing inflammation in a rat model of transient global cerebral ischemia/reperfusion. Biosci Rep. 2018;38:BSR20171562.
- Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a 6. new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev. 2001;53:135-159.
- 7. Szabó C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock. 1996;6:79-88. Shan J, Sun L, Wang D, Li X. Comparison of the neuroprotective effects
- 8. and recovery profiles of isoflurane, sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury. Int J Clin Exp Pathol. 2015;8:2001-2009.
- Eltzschig HK, Collard CD. Vascular ischaemia and reperfusion injury. Br 9. Med Bull. 2004;70:71-86.
- 10 Wang Y, Zhang X, Tian J, Liu G, Li X, Shen D. Sevoflurane alleviates LPS-induced acute lung injury via the microRNA-27a-3p/TLR4/MyD88/ NF-kB signaling pathway. *Int J Mol Med.* 2019;44:479-490. Herrmann IK, Castellon M, Schwartz DE, et al. Volatile anesthetics improve
- 11. survival after cecal ligation and puncture. Anesthesiology. 2013;119:901-906.
- 12. Zhu YM, Gao X, Ni Y, et al. Sevoflurane postconditioning attenuates reactive astrogliosis and glial scar formation after ischemia-reperfusion brain injury. Neuroscience. 2017;356:125-141
- Hwang JW, Jeon YT, Lim YJ, Park HP. Sevoflurane postconditioning-in-13. duced anti-inflammation via inhibition of the Toll-like receptor-4/nuclear factor kappa b pathway contributes to neuroprotection against transient global cerebral ischemia in rats. *Int J Mol Sci.* 2017;18:2347.
- Wang JY, Feng Y, Fu YH, Liu GL. Effect of sevofiurae anesthesia on brain is mediated by lncRNA HOTAIR. *J Mol Neurosci.* 2018;64:346-351. 14.
- Kim HC, Kim E, Bae JI, et al. Sevoflurane postconditioning reduces apoptosis by activating the JAK-STAT pathway after transient global cerebral ischemia in rats. J Neurosurg Anesthesiol. 2017;29:37-45.
- 16. Shi CX, Ding YB, Jin FYJ, et al. Effects of sevoflurane post-conditioning in cerebral ischemia-reperfusion injury via TLR4/NF-кВ pathway in rats. *Eur Rev Med Pharmacol Sci.* 2018;22:1770-1775. Pan L, Yang F, Lu C, Jia C, Wang Q, Zeng K. Effects of sevoflurane on rats
- 17 with ischemic brain injury and the role of the TREK-1 channel. Exp Ther Med. 2017:14:2937-2942
- Zhang Y, Tian SY, Li YW, et al. Sevoflurane preconditioning improving cerebral focal ischemia-reperfusion damage in a rat model via PI3K/Akt signaling pathway. Gene. 2015;569:60-65.

- Wen XR, Fu YY, Liu HZ, et al. Neuroprotection of sevoflurane against ischemia/reperfusion-induced brain injury through inhibiting JNK3/Caspase-3 by enhancing Akt signaling pathway. Mol Neurobiol. 2016;53:1661-1671.
- 20. Li B, Sun J, Lv G, et al. Sevoflurane postconditioning attenuates cerebral 2. P. J. Suri, Y. G. et al. Secondar post-outhorning methods and the second ischemia-reperfusion injury via protein kinase B/nuclear factor-erythroid 2-related factor 2 pathway activation. *Int J Dev Neurosci.* 2014;38:79-86. Nader ND, Li CM, Khadra WZ, Reedy R, Panos AL. Anesthetic myocardial protection with sevoflurane. *J Cardiothorac Vasc Anesth.* 2004;18:269-274.
- 21
- 22. Restin T, Kajdi ME, Schlapfer M, et al. Sevoflurane protects rat brain endothelial barrier structure and function after hypoxia-reoxygenation injury. PLoS One. 2017;12:e0184973
- Carrillo-Jimenez A, Deniz Ö, Niklison-Chirou MV, et al. TET2 regulates 23. the neuroinflammatory response in microglia. Cell Rep. 2019;29:697-713. e8
- 24 Patel AR, Ritzel R, McCullough LD, Liu F, Microglia and ischemic stroke: a double-edged sword. Int J Physiol Pathophysiol Pharmacol. 2013;5:73-90
- 25. Li XQ, Cao XZ, Wang J, Fang B, Tan WF, Ma H. Sevoflurane preconditioning ameliorates neuronal deficits by inhibiting microglial MMP-9 expression after spinal cord ischemia/reperfusion in rats. Mol Brain. 2014;7:69.
- 26. Morgan SC, Taylor DL, Pocock JM. Microglia release activators of neuronal proliferation mediated by activation of mitogen-activated protein kinase, phosphatidylinositol-3-kinase/Akt and delta-Notch signalling cas-cades. *J Neurochem.* 2004;90:89-101.
- Ma Y, Wang J, Wang Y, Yang GY. The biphasic function of microglia in ischemic stroke. *Prog Neurobiol.* 2017;157:247-272. 27.
- Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial 28 response to local brain injury in vivo. Nat Neurosci. 2005;8:752-758
- 29. Perego C, Fumagalli S, De Simoni MG. Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. *J Neuroinflammation*. 2011;8:174.
- Dang DD, Saiyin H, Yu Q, Liang WM. Effects of sevoflurane precondition-ing on microglia/macrophage dynamics and phagocytosis profile against 30 cerebral ischemia in rats. CNS Neurosci Ther. 2018;24:564-571.
- Zhang D, Chiu KM, Wang W, Sun D. Effects of conditioning with sevoflu-31. rane before reperfusion on hippocampal ischemic injury and insulin-like growth factor-1 expression in rats. *Chin J Physiol.* 2013;56:236-242. Toner CC, Connelly K, Whelpton R, et al. Effects of sevoflurane on do-
- 32. pamine, glutamate and aspartate release in an in vitro model of cerebral ischaemia. Br J Anaesth. 2001;86:550-554.
- Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular dis-33. ease. Arterioscler Thromb Vasc Biol. 2005;25:29-38.
- Canas PT, Velly LJ, Labrande CN, et al. Sevoflurane protects rat mixed 34. cerebrocortical neuronal-glial cell cultures against transient oxygen-glucose deprivation: involvement of glutamate uptake and reactive oxygen species. *Anesthesiology*. 2006;105:990-998.
- Pape M, Engelhard K, Eberspächer E, et al. The long-term effect of sevo-35. flurane on neuronal cell damage and expression of apoptotic factors after cerebral ischemia and reperfusion in rats. *Anesth Analg.* 2006;103:173-179, table of contents

Date of submission: April 9, 2020 Date of decision: April 21, 2020

Date of acceptance: April 27, 2020

Date of web publication: